https://www.selleckchem.com/mTOR.html
This study aimed to elucidate the residual disease distribution and recurrence patterns in patients with ESCC responding to NAC. To appropriately plan a prospective trial for the organ preservation approach which includes additional chemoradiotherapy in patients who responded to NAC, the distribution of residual disease needs to be elucidated. Given that the residual tumor is located in the regional field, chemoradiotherapy can be safely added to eliminate the residual disease. Overall, 483 patients with resectable ESCC who received NAC followed by
إعجاب
علق
شارك
